Opioid Antagonist Market Analysis

Drug Type (Buprenorphine, Naltrexone, Bunavail)

The buprenorphine segment is estimated to hold 52% share of the global opioid antagonist market by 2036. Primarily owing to its excellent clinical profile. In 2020, an estimated 1.7 million individuals reported taking buprenorphine as directed by doctor. The drug has great efficiency in managing addiction, with low potential for abuse as well as relatively mild adverse effects and its favorable formulary coverage are some of the factors that can be attributed to the high adoption of this drug.

End User (Hospitals, Private Clinics)

The hospital segment in the opioid antagonist market is anticipated to garner significant growth during the forecast period, owing to the increasing patient pool for opium and alcohol dependency. Moreover, the critical condition of the individual addicted to drugs, and the need for specific treatment is estimated to boost the segment’s growth.

Our in-depth analysis of the global market includes the following segments:

Drug Type	Buprenorphine Naltrexone Bunavail
End User	Hospitals Private Clinics

Frequently Asked Questions (FAQ)

Increased investments in healthcare, rising awareness, and increase in public health initiatives are some of the major growth drivers for the opioid antagonist market.

The market size of opioid antagonists is anticipated to attain a CAGR of 13% over the forecast period, i.e., 2024-2036.

The major players in the market are Alkermes., Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, Orexo AB, Camurus AB, Acura Pharmaceuticals., Collegium Pharmaceutical, AstraZeneca, Viatris Inc., Catalent, and others.

The Buprenorphine segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Opioid Antagonist Market Analysis